

*Amendments to the Claims*

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-62. (cancelled)

63. (currently amended) An isolated peptide consisting of at most 14 amino acid residues in length, ~~comprising~~ which comprises an oligopeptide selected from the group consisting of:

QAFTFSPTYK (SEQ ID NO:638);

LVVDFSQFSR (SEQ ID NO:620);

NVSIPWTHK (SEQ ID NO:625); and

SAICSVVRR (SEQ ID NO:653).

64. (previously presented) An immunogenic composition comprising the peptide of claim 63 and a pharmaceutically acceptable carrier.

65. (withdrawn) An immunogenic composition comprising the peptide of claim 63 and a liposome.

66. (previously presented) An immunogenic composition comprising the peptide of claim 63 and one or more second peptides, wherein said one or more second peptides is a cytotoxic T cell (CTL)-inducing peptide or a helper T cell (HTL)-inducing peptide.

67. (previously presented) The immunogenic composition of claim 66, further comprising a pharmaceutically acceptable carrier.

68. (withdrawn) The immunogenic composition of claim 66, wherein said cytotoxic T cell (CTL)-inducing peptide is 15 amino acids or less in length.

69. (previously presented) The immunogenic composition of claim 66, wherein said helper T cell (HTL)-inducing peptide comprises a pan-DR-binding epitope; and wherein said pan-DR-binding epitope comprises the peptide aKXVWANTLKAAa (SEQ ID NO:3877), wherein "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanine or L-alanine.

70. (withdrawn - currently amended) An immunogenic composition comprising:

(i) an isolated peptide consisting of at most 14 amino acid residues in length, ~~comprising~~ which comprises an oligopeptide selected from the group consisting of:

QAFTFSPTYK (SEQ ID NO:638);

LVVDFSQFSR (SEQ ID NO:620);

NVSIPWTHK (SEQ ID NO:625); and

SAICSVVRR (SEQ ID NO:653); and

(ii) one or more second peptides, wherein said one or more second peptides is a cytotoxic T cell (CTL)-inducing peptide or a helper T cell (HTL)-inducing peptide; wherein the isolated peptide of (i) and the one or more second peptides of (ii) are joined to form a fusion protein.

71. (withdrawn) The immunogenic composition of claim 70, wherein the isolated peptide of (i) and the one or more second peptides of (ii) are joined by spacer or linker amino acids to form the fusion protein.

72. (new) The immunogenic composition of claim 63, wherein the isolated peptide consists of between 9 and 11 amino acid residues in length.

73. (new) The immunogenic composition of claim 63, wherein the isolated peptide consists of 9 or 10 amino acid residues in length.

74. (new) The immunogenic composition of claim 63, wherein the isolated peptide consists of 13 amino acid residues or less in length.

75. (new) The immunogenic composition of claim 70, wherein the isolated peptide consists of between 9 and 11 amino acid residues in length.

76. (new) The immunogenic composition of claim 70, wherein the isolated peptide consists of 9 or 10 amino acid residues in length.

77. (new) The immunogenic composition of claim 70, wherein the isolated peptide consists of 13 amino acid residues or less in length.